John H. Beigel

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination

Sharon E. Frey, Lindsey R. Baden, Hana M. El Sahly, Richard T. Davey et autres

Introduction: Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is being used to mitigate disease in the current global mpox outbreak, but a global vaccine shortage may limit large scale vaccination. Methods: Participants were randomized 1:1:1 to receive two doses of MVA-BN administered 28 …

us, de (code pays fourni par la source)

Progress on the pathway to long COVID treatments

Robert W. Eisinger, Joseph J. Breen, John H. Beigel, Elizabeth Geerling et autres

us (code pays fourni par la source)

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

David Diemert, Daniel S. Graciaa, Bo Zhang, Nadine Rouphael et autres

Covid-19 vaccines are updated to match circulating strains based on reasoning that better strain-matched immunogenicity should provide better protection. Randomized evidence with disease endpoints to support strain matching is lacking. We evaluated COVID-19 incidence among adults randomized to a second booster of …

us (code pays fourni par la source)

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia

Nicholas Turner, Toshimitsu Hamasaki, Sarah B. Doernberg, Thomas P. Lodise et autres

Importance: Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus bacteremia without requiring long-term intravenous access. Objective: To evaluate the efficacy and safety of dalbavancin vs standard therapy for completion of treatment of complicated S …

us, fr, ca (code pays fourni par la source)

A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities

Courtney Luterbach, Dana K. Pasquale, Heather Henderson, Eric Cober et autres

With limited treatments for carbapenem-resistant Klebsiella pneumoniae (CRKp), curtailing transmission is critical. We applied a network analysis using epidemiological admission data and bacterial genetics to characterize CRKp spread among patients in 16 acute care hospitals linked to 217 other healthcare facilities in …

us, sg (code pays fourni par la source)

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Robert L. Atmar, Kirsten E. Lyke, Christine M. Posavad, Meagan E. Deming et autres

BACKGROUND: Mucosal immunity plays a critical role in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and replication. Understanding the capacity of coronavirus disease 2019 (COVID-19) vaccines to elicit both mucosal and systemic antibodies could help optimize vaccination strategies. METHODS: We …

us (code pays fourni par la source)

Polyclonal and Monoclonal Antibodies for the Treatment and Prevention of Influenza

John H. Beigel, David Oldach

While at least 8 monoclonal and 3 polyclonal antibody products have been tested in clinical trials for the treatment of influenza, no products have been licensed, and most have stopped clinical development. The COVID-19 pandemic demonstrated that these approaches, especially monoclonal antibodies, …

us (code pays fourni par la source)

Navigating the path forward for evidence-based management of long COVID

Joseph J. Breen, Robert W. Eisinger, Sarah W. Read, John H. Beigel et autres

us (code pays fourni par la source)

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Youyi Fong, Lauren Dang, Bo Zhang, Jonathan Fintzi et autres

For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) …

us (code pays fourni par la source)

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Surender Khurana, Lisa R. King, Jody Manischewitz, Olivia Posadas et autres

us (code pays fourni par la source)

Prospective cohort study of patient demographics, viral agents, seasonality, and outcomes of influenza-like illness in Mexico in the late H1N1-pandemic and post-pandemic years (2010-2014)

Arturo Galindo‐Fraga, Paola del Carmen Guerra-de-Blas, Ana A. Ortiz‐Hernández, Kevin Rubenstein et autres

Objectives: Influenza-like illness (ILI) caused by respiratory viruses results in various respiratory clinical manifestations. The ILI002 prospective observational cohort study aimed to describe viral agents, seasonality, and outcomes of patients with ILI during four seasons in the influenza H1N1-pandemic and post-pandemic years …

mx, us, gb, ca (code pays fourni par la source)

SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir

Kanal Singh, Kevin Rubenstein, Viviane Callier, Adam Rupert et autres

BACKGROUND: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to understanding antiviral efficacy in the multicenter Adaptive COVID-19 Treatment Trial 1, which …

us (code pays fourni par la source)